Members of the Council on Therapeutics unpack two ASHP policies adopted in the 2025 House of Delegates— one addressing the FDA’s proposal to change drug naming conventions, and the other requiring height and weight on certain medication orders. They share why these policies matter, the challenges encountered during the policy process, and the improvements they hope to see in patient care as a result.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This session focuses on various pharmacogenomics implementation models in oncology. Presenters discuss how pharmacogenomics was implemented at their respective institution, how each addressed unique barriers to implementation, and considerations for scalability, sustainability, and expansion of pharmacogenomics testing in oncology over the next 5+ years. CE for this episode expires two years after publication.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, the team from The Ohio State University Wexner Medical Center discusses their award-winning ASHP Best Practices submission.  They share how the program leveraged the unique expertise of pharmacist informaticists to take advantage of  EHR and build tools to automate the selection of preferred biosimilar, iron and Biosimilars, Iron, and 505(b)(2)  products based on the patient's insurance and hospital formulary preferences and time to payor approval for patients, reduced the administrative burden of the PA process, and improved the quality of our patient care.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

ASHP’s education director, Hannah Post is joined by Angela Cassano, president of Pharmfusion Consulting, LLC, William Hammonds, clinical pharmacy manager at West Virginia University Medicine, and Carrington Huneycutt, director of clinical pharmacy at Tandem Health, South Carolina, as they discuss their upcoming Midyear session that focuses on implementation and evolution of clinical pharmacy technician roles. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Pharmacists providing care to patients following toxicologic ingestions of medications and other substances are often relied upon for treatment and monitoring recommendations. Many pharmacists do not routinely care for patients following toxicologic ingestions of medications or other substances and are unfamiliar with clinical presentation of various toxidromes and ultimately management strategies. This episode covers anticholinergic, cholinergic, sedative-hypnotic, opioid, sympathomimetic, serotonin syndrome, neuroleptic malignant syndrome, and malignant hypethermia toxidromes and discusses the clinical presentation and causative medications/substances and general treatment approaches, with an emphasis on antidotes for specific toxidromes including physostigmine, naloxone, flumazenil, atropine, and pralidoxime. CE expires two years from when this episode was originally published.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, we dive into the essentials of beyond-use dating (BUD) in sterile compounding. What exactly is a BUD, and how does it differ from a manufacturer’s expiration date? We’ll break it down, explore key insights from USP <797>, and highlight what every sterile compounder needs to know. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Discover the essential contributions of pharmacists in patient care with We’re Your Pharmacist, a monthly podcast from ASHP. This episode features Charrai Byrd, director of pharmacy services at New York-Presbyterian Hospital, as he shares what drew him to a career in pharmacy. Gain insights into the diverse opportunities within the pharmacy profession and learn how pharmacists are making a difference every day. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast explores unique opportunities for pharmacists to pursue a Fulbright Scholar Award, highlighting pathways for academic exchange, research, and global health collaboration. Featuring insights from a recent Fulbright recipient, the discussion covers how pharmacists can contribute to and benefit from international scholarship and cultural diplomacy. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

ASHP’s senior education director, Cindy Von Heeringen is joined by James Hoffman, senior vice president of quality and safety, member, pharmacy and pharmaceutical sciences at St. Jude Children's Research Hospital, and Joe DiPiro, professor emeritus at Virginia Commonwealth University, School of Pharmacy, as they discuss their upcoming Midyear session that focuses on relevant trends in the external environment that will have a major impact on health-system pharmacy practice over the next five years. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode discusses the remainder of the results of the work from home survey conducted in 2024 by members of the Section of Specialty Pharmacy Practitioners Advisory Group on Operational and Workforce Development.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.